Related coverage linked through entity extraction aliases.
Aug 24, 2026
A study in Diabetologia shows type 2 diabetes in lean Africans is driven by insulin shortage, not insulin resistance, and may require different treatment than standard guidelines. The study analyzed data from over 3,300 African adults and found distinct complication patterns between lean and overweight patients.
Aug 19, 2026
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
Aug 17, 2026
Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
Jul 25, 2026
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
Jul 09, 2026
New research shows obesity-associated immune checkpoint inhibitor efficacy depends on the diet–gut microbiome axis rather than metabolic dysfunction. Human-to-mouse fecal microbiota transplants from high-BMI donors enhanced ICI efficacy, while a review outlines obesity-related inflammation's role in lung cancer immunotherapy outcomes and biomarkers.
Aug 04, 2026
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
Aug 04, 2026
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
May 21, 2026
A four-week dietary intervention reduced biological age in adults aged 65-75, with the strongest effect from an omnivorous high-carbohydrate diet. The Aging Cell study used 20 biomarkers. Longer-term research is needed.
Jul 18, 2026
A cross-sectional study shows that type 2 diabetes and body mass index independently worsen arterial stiffness, with BMI having a greater impact. No synergy was found between the two risk factors.
Jul 17, 2026
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
May 28, 2026
NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.
May 14, 2026
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
May 13, 2026
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
May 12, 2026
Rhythm reported Q1 2026 IMCIVREE revenue of $60.1 million and said more than 150 patient start forms were received after U.S. approval in acquired hypothalamic obesity. The company also cited European authorization and a Japanese application under review.
Apr 08, 2026
Researchers have used a machine learning model called AI-IR to demonstrate that insulin resistance is a risk factor for 12 types of cancer. The tool analyzes nine clinical parameters from standard health checkups to predict insulin resistance at population scale. This provides the first large-scale evidence linking insulin resistance to multiple cancers.
Apr 07, 2026
Boots has launched an in-store weight loss service across 17 UK locations, offering face-to-face consultations for weight-loss injections like Wegovy and Mounjaro. The service includes a 10-week free weight loss programme and 12-month aftercare, with prices starting at £99.97 for Wegovy. This marks the first high street pharmacy to provide such in-person weight loss treatment consultations.
Mar 15, 2026
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Mar 20, 2026
Novo Nordisk received FDA approval for a 7.2-mg semaglutide dose marketed as Wegovy HD for adult patients with obesity who have tolerated the standard 2.4-mg dose. The approval came through the FDA's new Commissioner's National Priority Voucher pilot program.
Mar 20, 2026
A Cleveland Clinic study of nearly 8,000 patients found minimal weight regain one year after stopping semaglutide or tirzepatide, contrasting with clinical trial results. Meanwhile, Eli Lilly's retatrutide and Roche's petrelintide continue development as next-generation obesity treatments.
Mar 14, 2026
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
